__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

This page is specifically intended to support patients who have been prescribed KESIMPTA®▼ (ofatumumab) by a UK healthcare provider. If you have any questions about your medicine, ask your doctor, nurse or pharmacist and read the patient information leaflet provided with your medicine.

 

Thumbnail image of Patient Welcome Booklet

Patient Welcome Booklet 

A booklet about KESIMPTA, which discusses how it works, potential side effects, and how to maintain your well-being. It also contains an injection diary, so you can keep track of your treatment progress.

Download

 

KESIMPTA Sensoready® pen: Instructions for patient

A short video explaining how to prepare and administer KESIMPTA.

Thumbnail image of Kesimpta patient alert card

KESIMPTA Patient Alert Card

A card that contains your contact details, as well as those of your healthcare professional, a space for you to record your medication, a travel letter and some information about the side effects that are possible with KESIMPTA treatment.

To obtain your card, please ask your healthcare professional.

 
Rate this content: 
No votes yet
UK | October 2021 | 157300

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See yellowcard.mhra.gov.uk for how to report side effects.

 

×

Ask Speakers

×

Medical Information Request

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You should also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk.
By reporting side effects you can help provide more information on the safety of this medicine.